TY - JOUR
T1 - Antinociception depends on the presence of G protein γ2- subunits in brain
AU - Varga, Eva V.
AU - Hosohata, Keiko
AU - Borys, Dariusz
AU - Navratilova, Edita
AU - Nylen, Anders
AU - Vanderah, Todd W.
AU - Porreca, Frank
AU - Roeske, William R.
AU - Yamamura, Henry I.
N1 - Funding Information:
The authors assert that the experimental protocols have been approved by the institutional ethics committee. The authors thank Jennifer Logan for technical assistance in the analgesic assays. This work was supported by grants from the National Institute of Health.
PY - 2005/1/31
Y1 - 2005/1/31
N2 - We have shown previously [Hosohata, K., Logan, J.K., Varga, E., Burkey, T.H., Vanderah, T.W., Porreca, F., Hruby, V.J., Roeske, W.R., Yamamura, H.I., 2000. The role of the G protein γ2 subunit in opioid antinociception in mice. Eur. J. Pharmacol. 392, R9-R11] that intracerebroventricular (i.c.v.) treatment of mice with a phosphorothioate oligodeoxynucleotide antisense to the γ2 subunit (Gγ2) of the heterotrimeric G proteins (antisense ODN) significantly attenuates antinociception by a δ-opioid receptor agonist. In the present study, we examined the involvement of Gγ2 in antinociception mediated by other (μ- or κ-opioid, cannabinoid, α2-adrenoreceptor) analgesic agents in a warm (55°C) water tail-flick test in mice. Interestingly, i.c.v. treatment with the antisense ODN attenuated antinociception by each analgesic agent. Missense phosphorothioate oligodeoxynucleotide treatment, on the other hand, had no effect on antinociception mediated by these agonists. The antinociceptive response recovered in 6 days after the last antisense ODN injection, indicating a lack of nonspecific tissue damage in the animals. These results suggest a pervasive role for the G protein γ2 subunits in supraspinal antinociception.
AB - We have shown previously [Hosohata, K., Logan, J.K., Varga, E., Burkey, T.H., Vanderah, T.W., Porreca, F., Hruby, V.J., Roeske, W.R., Yamamura, H.I., 2000. The role of the G protein γ2 subunit in opioid antinociception in mice. Eur. J. Pharmacol. 392, R9-R11] that intracerebroventricular (i.c.v.) treatment of mice with a phosphorothioate oligodeoxynucleotide antisense to the γ2 subunit (Gγ2) of the heterotrimeric G proteins (antisense ODN) significantly attenuates antinociception by a δ-opioid receptor agonist. In the present study, we examined the involvement of Gγ2 in antinociception mediated by other (μ- or κ-opioid, cannabinoid, α2-adrenoreceptor) analgesic agents in a warm (55°C) water tail-flick test in mice. Interestingly, i.c.v. treatment with the antisense ODN attenuated antinociception by each analgesic agent. Missense phosphorothioate oligodeoxynucleotide treatment, on the other hand, had no effect on antinociception mediated by these agonists. The antinociceptive response recovered in 6 days after the last antisense ODN injection, indicating a lack of nonspecific tissue damage in the animals. These results suggest a pervasive role for the G protein γ2 subunits in supraspinal antinociception.
KW - Antinociception
KW - Cannabinoid receptor agonist
KW - Clonidine
KW - G protein γ subunit
KW - Guanine nucleotide binding protein
KW - Opioid receptor agonist
UR - http://www.scopus.com/inward/record.url?scp=12844275517&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=12844275517&partnerID=8YFLogxK
U2 - 10.1016/j.ejphar.2004.11.062
DO - 10.1016/j.ejphar.2004.11.062
M3 - Article
C2 - 15680258
AN - SCOPUS:12844275517
SN - 0014-2999
VL - 508
SP - 93
EP - 98
JO - European Journal of Pharmacology
JF - European Journal of Pharmacology
IS - 1-3
ER -